2017
DOI: 10.1016/j.acuroe.2017.08.008
|View full text |Cite
|
Sign up to set email alerts
|

Adjuvant intravesical treatment for non-muscle invasive bladder cancer: The importance of the strain and maintenance

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
14
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(15 citation statements)
references
References 14 publications
1
14
0
Order By: Relevance
“…A recent meta-analysis comparing 10 BCG substrains was unable to find the best substrain, 16 and a previously published retrospective study performed by Guerrero-Ramos et al found similar recurrence-free survival rates between patients who had received BCG Connaught and those who had received BCG Tice. 17 Similar conclusions were reached by Unda-Urzaiz et al, who compared BCG Tokyo, Russian, Tice, Connaught and RIVM; 18 Krajewski et al, who compared BCG Tice, Moreau and RIVM; 14 and a recent study that compared the BCG Moreau and Tice substrains. 19 However, Rentsh et al demonstrated that BCG Connaught was significantly more effective in terms of recurrence-free survival than BCG Tice.…”
Section: Safety and Efficacysupporting
confidence: 54%
“…A recent meta-analysis comparing 10 BCG substrains was unable to find the best substrain, 16 and a previously published retrospective study performed by Guerrero-Ramos et al found similar recurrence-free survival rates between patients who had received BCG Connaught and those who had received BCG Tice. 17 Similar conclusions were reached by Unda-Urzaiz et al, who compared BCG Tokyo, Russian, Tice, Connaught and RIVM; 18 Krajewski et al, who compared BCG Tice, Moreau and RIVM; 14 and a recent study that compared the BCG Moreau and Tice substrains. 19 However, Rentsh et al demonstrated that BCG Connaught was significantly more effective in terms of recurrence-free survival than BCG Tice.…”
Section: Safety and Efficacysupporting
confidence: 54%
“…In 43 of these studies (70%), BCG was used in all patients (100% treatment rate). 16,17,19,[21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][40][41][42][43][44]46,49,51,54,56,57,[61][62][63]65,68,69,[72][73][74][75][76] BCG therapy was an inclusion criterion for some of these studies, which contributed to this high rate. In the remaining 18 studies (30%), the reported use of BCG instillations in HR-NMIBC patients ranged from 3% to 86%.- 18,20,39,45,47,48,50,…”
Section: Treatment Patternsmentioning
confidence: 99%
“…In the remaining 18 studies (30%), the reported use of BCG instillations in HR-NMIBC patients ranged from 3% to 86%.- 18,20,39,45,47,48,50,52,53,55,[58][59][60]64,66,67,70,71 Thirty-five studies reported on the use of BCG induction therapy specifically, 16,17,20-22,24-28,31,33-37,40,42,45,47,49,51,52, ClinicoEconomics and Outcomes Research 2022:14 https://doi.org/10.2147/CEOR.S341896 DovePress 37 54,56,57,59,61,63,65,68,74,75,77,78 of which 27 (77%) reported the use of BCG induction in all patients (100%). 16,17,21,22,[24][25][26][27][28]31,[33][34][35][36][37]40,42,49,…”
Section: Treatment Patternsmentioning
confidence: 99%
See 2 more Smart Citations